NCT04577729View on ClinicalTrials.gov

The IRMI-FMT Trial

NATerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 21, 2021

Primary Completion Date

June 7, 2023

Study Completion Date

June 7, 2023

Conditions
Fecal Microbiota TransplantationMalignant Melanoma Stage IIIMalignant Melanoma Stage IV
Interventions
PROCEDURE

Allogenic Fecal Microbiota Transplantation

Patients receiving stool from prior malignant melanoma (MM) patients in remission for at least 1 year after Checkpoint Inhibitor Treatment.

PROCEDURE

Autologous Fecal Microbiota Transplantation

Patients receiving their own stool in terms of sham FMT.

Trial Locations (1)

Unknown

Medical University of Graz, Graz

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Medical University of Graz

OTHER

NCT04577729 - The IRMI-FMT Trial | Biotech Hunter | Biotech Hunter